

实验研究

基于 miRNA - 124 探讨益脾养肝方对大鼠肝癌前病变影响的实验研究^{*}魏海梁^{1**} 曹妮² 李京涛^{1***} 闫曙光² 司明明¹ 鞠迪²

(1. 陕西中医药大学附属医院, 陕西 咸阳 712000; 2. 陕西中医药大学, 陕西 咸阳 712046)

摘要: **目的** 探讨益脾养肝方对二乙基亚硝胺(diethylnitrosamine, DEN)诱导大鼠肝癌前病变模型,以益脾养肝方(YPYGF)组方干预后各组大鼠不同肝细胞形态变化,以及对肝细胞中 miRNA - 124 变化的影响。**方法** 以 DEN 诱导 180 只 Wistar 大鼠肝癌前病变模型,成模后随机分为 6 组各 30 只(空白组、DEN 组、护肝片组、低剂量组、中剂量组、高剂量组),给予不同干预后,通过 HE 染色观察各组肝细胞形态变化,并采用免疫荧光染色法及 qRT - PCR 法检测肝细胞中 miRNA - 124 表达水平变化,以研究益脾养肝方对大鼠模型肝癌前病变的影响。**结果** 与 DEN 组比较,益脾养肝方干预下肝癌前病变大鼠肝组织内 miRNA - 124 表达水平显著升高,肝癌前病变组织及细胞凋亡改善显著,各组间比较,YPYGF 高剂量组作用最明显。**结论** 益脾养肝方能够有效修复受损的肝细胞,改善肝脏功能,延缓肝癌前病变进展,其治疗机制可能与改善肝细胞中抑癌因子 miRNA - 124 的表达,进而抑制肝细胞凋亡的作用相关。

关键词: 益脾养肝方;肝癌前病变;miRNA - 124**中图分类号:** R735.7 **文献标识码:** A **文章编号:** 2096 - 1340(2020)05 - 0060 - 06**DOI:** 10. 13424/j. cnki. jsctcm. 2020. 05. 016

An Experimental Study on the Effect of Yipi Yanggan Formula on Precancerous Lesions of Hepatoma in Rats Based on miRNA - 124

Wei Hailian¹, Cao Ni², Li Jingtao¹, Yan Shuguang², Si Mingming¹, Ju Di²

(1. Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang Shaanxi, 712000;

2. Shaanxi University of Chinese Medicine, Xianyang Shaanxi 712046)

Abstract: **Objective** To investigate the effect of Yipi Yanggan Formula (YPYGF) on the precancerous lesion model induced by diethylnitrosamine (DEN) in rats. After intervention with YPYGF, the morphological changes of different hepatocytes and the changes of miR - 124 in hepatocytes were observed. **Methods** 180 Wistar rats with precancerous lesions induced by DEN were randomly divided into 6 groups (blank group, DEN group, Hugaan tablet group, low - dose group, medium - dose group and high - dose group). After different interventions, the morphological changes of hepatocytes were observed by HE staining, and the expression of miR - 124 in hepatocytes was detected by immunofluorescence staining and qRT - PCR to study the effect of YPYGF on precancerous lesion of rat model. **Results** Compared with DEN

^{*} **基金项目:** 国家自然科学基金项目(81904192);陕西省科技厅科研基金(2018KJXX - 093, 2020SF - 338);陕西中医药大学学科创新团队建设项目(2019 - YL05)。

^{**} **作者简介:** 魏海梁(1978 -), 副主任医师,研究方向:主要从事中西医结合消化系统疾病的临床研究及教学。E - mail: 86888694@qq. com

^{***} **通讯作者:** 李京涛,主任医师,医学博士。E - mail: lijingtao555@163. com